$63.62+0.01 (+0.02%)
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States.
Tarsus Pharmaceuticals, Inc. in the Healthcare sector is trading at $63.62. The stock is currently 25% below its 52-week high of $85.25, remaining 3.8% below its 200-day moving average. Technical signals show oversold RSI of 28 and bearish MACD signal, explaining why TARS maintains its current current market pressure. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for t...
Amgen (AMGN) delivered earnings and revenue surprises of +8.87% and +1.71%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Recent performance and business snapshot Tarsus Pharmaceuticals (TARS) has attracted fresh attention after recent trading, with the stock closing at US$70.12 and showing mixed share price moves over the past week, month and past 3 months. The company focuses on eye care therapies in the United States, with commercial revenue of US$451.36 million and a reported net loss of US$66.418 million. This puts profitability and growth plans in clear focus for investors. See our latest analysis for...
Tarsus Pharmaceuticals recently dosed the first participant in its Phase 2 Calliope trial of TP-05, an investigational oral therapy aimed at preventing Lyme disease in approximately 700 at-risk adults across endemic U.S. regions. This program targets a large unmet need as a potential first-in-class, non-vaccine, drug-based prophylactic for Lyme disease, where no FDA-approved preventive drugs currently exist. We’ll now examine how TP-05’s Phase 2 progress, building on earlier “tick kill”...
On Thursday, Tarsus Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 76 to 82. Looking For The Best Stocks To Buy And Watch? Start Here IBD's proprietary rating tracks share price performance with a 1 (worst) to 99 (best) score.
This ophthalmic biotech reported a notable insider sale as it advances treatments for Demodex blepharitis and other eye diseases.